Iovance CFO Bellemin departs effective June 30; SVP Finance Rosinack named interim CFO

IOVANCE BIOTHERAPEUTICS, INC.

CFO Jean-Marc Bellemin's resignation accelerated from July 10 to June 30, 2025 by mutual agreement.
Matthew W. Rosinack appointed interim Principal Financial Officer and Principal Accounting Officer effective June 30, 2025.
Rosinack has been SVP, Finance since Sept 2021; prior roles at Berkeley Lights, ZELTIQ Aesthetics, FormFactor, and PwC.
No arrangements, family relationships, or transactions requiring disclosure in connection with Rosinack's appointment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.